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Abstract
Background: Emerging trends and new policies suggest that more cancer patients might die at home in the
future. However, not all have equal chances of achieving this. Furthermore, there is lack of evidence to support
that those who die at home experience better care and a better death than those who die as inpatients. The
QUALYCARE study aims to examine variations in the quality and costs of end-of-life care, preferences and palliative
outcomes associated with dying at home or in an institution for cancer patients.
Methods/Design: Mortality followback survey (with a nested case-control study of home vs. hospital deaths)
conducted with bereaved relatives of cancer patients in four Primary Care Trusts in London. Potential participants are
identified from death registrations and approached by the Office for National Statistics in complete confidence. Data
are collected via a postal questionnaire to identify the informal and formal care received in the three months before
death and the associated costs, relatives’ satisfaction with care, and palliative outcomes for the patients and their
relatives. A well-established questionnaire to measure relatives’ views on the care integrates four brief and robust tools -
the Client Service Receipt Inventory, the Palliative Outcome Scale, the EQ-5 D and the Texas Revised Inventory of Grief.
Further questions assess patients and relatives’ preferences for place of death. The survey aims to include 500 bereaved
relatives (140 who experienced a home death, 205 a hospital death, 115 a hospice death and 40 a nursing home
death). Bivariate and multivariate analyses will explore differences in place of death and place of end-of-life care, in
preferences for place of death, patients’ palliative outcomes and relatives’ bereavement outcomes, in relation to place
of death. Factors influencing death at home and the costs of end-of-life care by place of death will be identified.
Discussion: Collecting data on end-of-life care retrospectively from bereaved relatives has ethical, practical and
scientific challenges. QUALYCARE has been carefully designed to address these challenges in a robust and ethically
sound population-based survey. By discovering variations in the underlying individual reality of place of death for
people dying from cancer and their families, this study will advance our understanding of end-of-life care and, we
hope, improve care for cancer patients and their families in the future.
Trial registration: National Institute of Health Research (NIHR) Clinical Research Network Portfolio. UKCRN7041.
Background
Extensive evidence shows that most members of the
public and patients prefer to be cared for and to die at
home [1-3]. However, a recent cross-national study of
death certificates showed that only a minority of
people dying from cancer achieve this (home deaths
ranging from 12.8% in Norway to 45.4% in the Nether-
lands)[4]. In many countries such as the UK, Italy,
Greece, Korea and Japan home deaths have been fall-
ing [5-9], but recently in the US and Canada there are
indications of a reversal of trends [10-12]. Strategic
national decisions were made for Medicare and Medi-
caid programs in the US and most recently by the
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Department of Health in the UK to focus on home-
based models of care to enable more people to die at
home [13,14].
Not all people with terminal cancer have equal
chances of dying at home, and some of the inequities
are well known. For example, patients living in
deprived areas are less likely to die at home. This
and another 16 factors are part of a robust interna-
tional model of factors influencing death at home in
cancer, derived from findings of 58 studies relating to
1.5 million patients [15]. This model is in place to
guide practice and policy in helping more terminally
ill cancer patients to die at home. However, there are
variations (individual and geographical) not yet
explained.
Enabling more patients to die in the place of their
choice is important. However, the real issue is at what
quality, and secondly, at what cost. There is little evi-
dence to support that those who die at home and their
relatives experience better care than those who die in
institutions such as hospitals, hospices or nursing
homes. There is a dearth of comparative studies on the
associated costs.
The QUALYCARE study has been designed to address
the lack of evidence on the quality and costs of end-of-
life care for people with cancer in relation to place of
death. Its primary aim is to examine variations in the
quality and costs of end-of-life care, preferences and
palliative outcomes associated with home vs. institu-
tional death in cancer. Secondary aims are to examine
whether the care, costs, preferences and outcomes asso-
ciated with death at home are the same in areas with
high vs. low home death rates and in areas with high vs.




Mortality followback postal survey with bereaved rela-
tives of people who died from cancer, with a nested
case-control study of home vs. hospital deaths, and
informed by a pilot study [16].
Finding out the views of bereaved relatives is impor-
tant for three main reasons. Firstly, because this is the
only way to get a population-based perspective on
end-of-life care, and an understanding of the use and
experiences of care (with reasonable evidence that their
evaluation of services matches those of patients)[17]
relating to a consistent time period close to the patient’s
death (defined in this study as the three months before
death). Secondly, relatives’ views are important as
research demonstrates their crucial role in caring and
supporting patients to die at home [15]. Thirdly, rela-
tives are often carers but also recipients of end-of-life
care (which includes bereavement support); surveying
bereaved relatives allows us to understand how well
they cope with their loss and grief.
Notwithstanding, bereaved relatives are a vulnerable
group and engaging in research can be distressing and
difficult for them. Few would currently accept the posi-
tion that bereavement research is unethical per se, parti-
cularly in light of research findings showing benefits as
perceived by bereaved relatives[18-21]. These studies
and our pilot study have indicated that most bereaved
relatives welcome the opportunity to make a contribu-
tion towards improving care for others by taking part in
research. Furthermore, using postal surveys of bereaved
relatives is a well established and accepted method of
research in end-of-life care, with tradition in the UK
and indeed recommended in the recent National End of
Life Care Strategy[14,22,23]. It has been shown that this
Table 1 Study objectives
Objective 1. To describe and compare home, hospital, hospice and nursing home deaths in terms of:
1.1. place where the patients’ spent most of the three months before death;
1.2. patients and relatives’ preferences for place of death;
1.3. patients’ palliative outcomes (symptoms and quality of life in the week before death; attainment of their preferred place of death) and
relatives’ outcomes (grief intensity; attainment of their preferred place of death);
1.4. use, type and costs of and relatives’ satisfaction with formal care received at home and in institutions in the three months before death
(including GP care, district nursing, specialist nursing, specialist home palliative care teams; nursing and medical care in hospitals, inpatient
hospices and nursing homes);
1.5. use, type and costs of informal care in the three months before death.
Objective 2. To describe and compare home vs. institutional deaths on the same five aspects as in objective 1;
Objective 3. To describe and compare deaths in high vs. low home death rate areas and high vs. low deprivation levels on the same five aspects as
in objective 1;
Objective 4. To determine the relative influence of different factors on death at home (vs. in institutions and vs. hospital deaths) and the amount of
variation in place of death they explain, comparing areas with high and low home death rates and with high and low deprivation levels;
Objective 5. To determine whether death at home (vs. in institutions and vs. hospital deaths) is independently associated with outcomes and costs,
comparing areas with high and low home death rates and with high and low deprivation levels.
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kind of surveys can be carried out in an ethical manner.
For these reasons, we have decided to conduct the
study, conscious of the ethical challenges and committed
to minimising the risks of harm and maximising the
benefits for potential participants. We have reviewed the
literature, consulted with experts in the field and con-
ducted a careful pilot study with 20 bereaved relatives
to decide on best design approaches.
A postal approach was chosen as the most appropriate
and practical data collection method, given the large
size of the study population and robust postal research
methodologies with bereaved relatives developed in the
UK. An RCT of postal vs. face-to-face methods using an
adapted version of the same questionnaire found that
response rates (52% vs. 56%) and respondents’ charac-
teristics did not differ significantly [23]. Although there
were more missing data in the postal version, postal
responders rated satisfaction and symptom control more
moderately, which may suggest lesser influence of social
desirability. Ethical issues were also taken into consid-
eration as a postal method allows more privacy and less
intrusion than face-to-face or telephone interviews.
The nested case-control study will identify people who
die at home (defined as the “cases”) and compare their
past exposure to suspected risk factors (for dying at
home) with that of patients who die in hospital (the
“controls”). The definition of cases in relation to place
of death is not as clear as in studies measuring disease
frequency, where those affected by the disease are con-
sidered the cases. Our approach was therefore to take
home deaths as the “cases”, given that these are rarer
than hospital deaths. The QUALYCARE case-control
study will compare the care received, preferences and
other risk factors for dying at home, rather than costs
or outcomes (for which place of death is seen as a
potential risk factor and not an outcome). Because the
association will be determined for each individual case-
control pair, the study will determine more accurately
than cross-sectional studies the potential for a causal
link between risk factors and death at home.
Finally, the study includes an economic evaluation of
costs and consequences. This takes a health service per-
spective but voluntary sector costs and informal care are
also valuated, at the market price that would have to be
paid by the NHS to provide these. The cost component
is the more exploratory part of the study, focused on
estimation rather than hypothesis testing, as so little is
known about the topic.
Setting
The survey takes place in four Primary Care Trust (PCT)
areas within London. London has the lowest home death
rates of all nine strategic health authorities in England
(18.5% in 2008) [24]. This is likely to reflect the influence
of what is known to be the strongest determinant of
death at home - hospital availability and use [15]. The
home death rate for cancer-related deaths is slightly
higher but also low (20%) and inner London variation
has been reported, with deprivation playing a role [25].
The four PCT areas in the study have contrasting cancer
home death rates and deprivation levels (within London).
Participants
Bereaved relatives of people aged 18 years or over who
died from cancer in a one year period (March 2009-
March 2010), and who lived in one of the PCTs in
study.
Identification and sampling
Bereaved relatives are identified from death registrations,
as the people who registered a cancer-related death
(informant). In a similar study across eight cancer net-
works in the UK (2002-03), this was found to be a
spouse or relative in 93% of the cases [26]. This identifi-
cation process is conducted in two waves (Nov 2009
and May 2010) in complete confidence by the Office for
National Statistics (ONS).
In each wave, the ONS team first identifies all cases of
death registered four to ten months prior to the date
invitation letters are planned to be sent out; they then
screen for further eligibility criteria (Table 2). There is
Table 2 Eligibility criteria
Inclusion criteria
• deceased last resident in one of the four PCTs in study, as recorded in the death registration;
• date of registration of death within four to ten months before invitation letters for participation are sent out;
• deceased aged 18 and over at time of death;
• cancer (ICD-10 codes C00-D48) recorded as “underlying cause of death” or in the lowest completed cause of death line in the death
certificate.
Exclusion criteria
• death registered by a coroner;
• place of death other than an NHS hospital, the deceased’s own home, a hospice or a nursing home;
• place of death unknown.
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no firm evidence of what is the most appropriate time-
frame to approach bereaved relatives for research (with
optimal balance between information accuracy and dis-
tress minimisation). A recent national survey in Italy
found the best timing in terms of responses rates was
four to six months after death [27]. We have established
a minimum of four months after the death has been
registered to contact the bereaved relatives, to avoid the
period of more intense grieving. Previous studies have
contacted people at a minimum of three months after
death registration. However, results from our pilot study
suggested this might still be too early for some. We
have therefore taken a more conservative approach with
view to minimise distress and potential harm.
After eligible people are identified, a sample is then
drawn by the ONS team. This is stratified by PCT and
place of death - 1) home, 2) hospice, 3) nursing home,
and 4) NHS hospital. The sample in each PCT includes:
all deaths that take place at home; all hospice deaths; all
nursing home deaths; and a random sample of NHS
hospital deaths.
Recruitment and consent
Invitation letters are sent by the ONS team to the infor-
mants in death registrations sampled for the study,
inviting them to take part and explaining how they had
been identified. Letters to potential participants in Wave
1 were sent in January 2010; letters for Wave 2 were
sent in July 2010.
The invitation letter first apologises in advance for any
distress caused. It then assures potential participants
that their contact details were not released and that
instead the ONS agreed to contact them on behalf of
the research team for the purposes of the study. Each
letter is enclosed with an information leaflet signed by
the Principal Investigator and the Director of Public
Health from the local Primary Care Trust (PCT),
explaining why the work is important and how it will be
used to help improve care (information leaflets available
from study website at http://www.kcl.ac.uk/qualycare).
Contact points are given if people wish to talk about the
study. The information leaflet, the study questionnaire, a
reply slip (for people to decline to take part if they wish
so), two freepost envelopes (one for the reply slip to be
sent to the ONS and one for the questionnaire to be
sent to the research team) and a leaflet with information
about bereavement (produced by the Royal College of
Psychiatrists) are also enclosed.
Potential participants are invited to complete and
return the completed questionnaire directly to the
research team. This is taken as consent to participate. If
they do not wish to take part in the study, they are
asked to return the reply slip to the ONS. Upon receipt,
they are flagged as non-participants and are not con-
tacted again. Two reminders, with a further copy of the
questionnaire, are sent by the ONS at two-weekly inter-
vals to those who do not respond.
Data collection
The data are collected at one point in time from each
participant by a postal self-completed questionnaire. A
follow-up telephone interview (of about 15 minutes)
may also take place, although this is entirely optional,
and only if participants write in the questionnaire they
agree and provide their contact details. The interview
aims to clarify information if appropriate (e.g. answers
which appears to be accidentally missing) and to talk
about the questionnaire, so the researcher ascertains the
impact and effect of the questionnaire on the participant
(to screen for distress and serious concerns). The period
of data collection is planned to be eight months, includ-
ing time for the second and last wave of questionnaires
to be returned and follow-up telephone interviews to be
made.
Questionnaire
The study uses an adapted short form of a questionnaire
developed by Ann Cartwright in the late 1960’s to mea-
sure patients’ experiences of the last year of life from
the perspective of their bereaved relatives [28]. Since
then, versions of Cartwright’s questionnaire have been
used successfully in a number of surveys [26,27,29-32]
We have integrated in it four brief and robust measure-
ment tools previously used in cancer and end-of-life
care studies (Table A in additional file 1). These tools
collect information on health and social care services
use and informal care (Client Service Receipt Inventory
- CSRI) [33,34], patient palliative outcomes in the week
prior to death (Palliative Outcome Scale - POS) [35,36],
health-related quality of life (EuroQoL EQ-5D) [37], and
respondents’ bereavement outcomes (Texas Revised
Inventory of Grief - TRIG). (38-40) Further questions
explore preferences for place of death, relevant local
issues and socio-demographic and clinical data. The for-
mat and navigation of the questionnaire was refined
according to cognitive theory literature[41]. The result-
ing QUALYCARE questionnaire has been piloted and
improved in a pilot study with 20 bereaved relatives,
recruited via the palliative medicine department of a
London hospital[16].
Completing the questionnaire takes about 60 minutes.
Participants are given the contact details of the research
team, should they need assistance.
Practical and operational arrangements
Once identified, all sampled cases are assigned study
identification (ID) numbers by the ONS team, who then
provides the research team with a spreadsheet of these
numbers (by PCT of residence, gender of the deceased
and place of death coded as home, hospice, nursing
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home or hospital). The spreadsheet enables the ONS
team and the research team to communicate using
study ID numbers with a view to prepare the question-
naire packs, conduct the mailings and monitor recruit-
ment. Questionnaire packs are prepared by the research
team using the spreadsheet to personalised each pack by
PCT and gender of the deceased (there are two versions
of the questionnaire - one related to female deceased
and one to male deceased). Questionnaires and reply
slips are also marked with the respective study ID num-
ber. The packs are then delivered to the ONS, where
address labels and personalised invitation letters are
included and postage is organised. The research team
manages the questionnaire returns and notifies the ONS
of study ID numbers to prevent follow-up mailings to
people who decline participation; ONS reports back to
the research team all declinations to participate (made
either by phone or post) with reasons if people volun-
teer them, as well as any complaints received.
Upon receipt of a completed questionnaire, the
research team records arrival into the spreadsheet,
checks completion, levels of distress and grief intensity,
and safely store the questionnaire in a locked cabinet in
a locked office in the team’s department. Access to the
data is restricted and controlled. If there is need for
clarifications regarding the questionnaire or follow-up to
assess the impact of the questionnaire on the participant
and potential distress, and provided the participant has
agreed to be contacted and provided contact details, a
member of the research team makes contact to arrange
a telephone interview.
At the end of each wave, the ONS provides the
research team with an anonymised and encrypted data-
set of all eligible cases of deaths in each of the PCTs
(including participants and non-participants) with indi-
vidual information on study ID numbers, PCT of resi-
dence, age, date of death occurrence, date of death
registration, underlying cause of death, other causes of
death, place of death, gender, place of birth, electoral
ward of last residence of the deceased and their rela-
tionship to the informant. These data are important to
understand what population is excluded from the
study and who decides not to take part. All informa-
tion is treated confidentially, following ONS regula-
tions and the data management guidelines of the
research team ’s department. The study has been
approved by an NHS Research Ethics Committee (REC
ref no.: 09/H0808/85).
Procedures to identifying and handling distress
Receiving the invitation letter and completing the ques-
tionnaire can lead to a reawakening of bereavement and
any associated distress or anger. It can also lead to dis-
closure of information by the participants which may
require follow-up action by the research team. For
example, it may prompt unresolved issues about
bereavement and grief in the participant. Published
guidelines by Colin Murray Parkes on how to conduct
ethical bereavement research are being followed [42]
and a series of measures are in place to identify and
deal with any distress, complaints and sensitive issues
arising in the course of the study (Table 3).
Table 3 Measures for handling distress and sensitive issues
1. Written protocol for dealing with queries and distress
This was made available to those involved in information giving and interviewing (members of the research team, the PI Department’s
administrative team, the ONS team) so they carry out these tasks sensitively, with attention to any distress (potential or real), and handling this
appropriately;
2. Communication log record
Conversations maintained with people approached for the study (or with anyone on their behalf) or with individuals requesting for information
about the study (e.g. via website feedback form) are recorded to facilitate review, as need be;
3. Screening for need to follow-up
A member of the research team reads and checks the questionnaire soon after its arrival, particularly the responses to questions on grief
intensity, to screen for cases which may require follow-up action. Should the participant agree to be contacted and write down in the
questionnaire her/his contact details, the researcher makes contact to ascertain the impact and effect of the questionnaire on the participant,
and to direct to sources of help if appropriate. The researcher approaches this with sensitivity and handles any distress appropriately.
◦ If specific concerns arise, the researcher informs the participant about sources of local support and asks the participant if s/he wishes to
be given the contact details or if he/she would like the researcher to contact local services for contacts/visits to be arranged;
◦ If the researcher has a high level of concern about a participant (e.g. if the researcher suspects a participant is very depressed and
possibly suicidal) this is discussed as a matter of urgency with the PI, who is a Consultant in Palliative Medicine with extensive clinical
experience of working with distressed family members and addressing their distress, to proceed with appropriate action to further assist
and aid the participant in question, if this is felt appropriate. Complaints are regarded as situations of high level of concern and treated in
the same manner.
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Data entry
Answers to the questionnaire are entered into a pre-
designed SPSS database (version 17.0). This excludes
any personal information that might have been provided
by the participant, such as contact details; these are kept
only in the paper questionnaire, which is securely stored
in a locked cabinet. Data entry is continuously moni-
tored through supervision meetings where a set of rules
develops and exceptions are discussed. A decision diary
with rules, exceptions and decisions constructs an audit
trail to enable transparency. Ten percent of the data are
double-entered and cross-checks identify the percentage
of items with discordances, missing data and systematic
errors (percentage of double-checked data to be adjusted
according to outcome of cross-checks). Once completed
and checked, the questionnaire database will then link
with the anonymised dataset provided by the ONS
(using study ID numbers).
Data analysis
Numbers of all cancer deaths, participants and non-par-
ticipants, including those ineligible and those who
decline to participate or do not reply will be reported in
a flowchart. Participants and non-participants will be
compared in terms of clinical and socio-demographic
variables of both the deceased and their relatives, to
investigate possible selection bias. The influence of place
of death and timing from death to first contact will also
be investigated. T-tests will be used to compare continu-
ous data which are normally distributed, Mann-Whitney
tests will be used with non-parametric continuous or
ordinal data, and c2 tests will be used with categorical
variables (significance level set at 0.05).
Place of death and place of end-of-life care
The data allow reporting the place of death for both
participants and non-participants. For participants, com-
parisons will be made between place of death as
reported in the death registrations and as reported by
the bereaved relatives, examining percentage and type of
disagreements. Place of death will also be compared
with the place where the patients spent most part of the
three months before death, as reported by their relatives
(objective 1.1 in Table 1).
Descriptive and bivariate analysis of home, hospice, nursing
home, and hospital deaths
Frequency tables and descriptive statistics will be used
to compare home with hospital, hospice and nursing
home deaths in terms of preferences for place of death
(objective 1.2) - of patients and of their relatives, and
for the latter at three months prior to death, changes in
the three months before death (reported retrospectively)
and post-death. Numbers and percentages (with 95%
CIs) where the patient and the relative disagreed regard-
ing place of death and the type of disagreements will
also be reported. c2 tests will be used to test for
differences.
Frequency tables and descriptive statistics will report
outcomes by place of death (objective 1.3). These will
show numbers and percentages of patients who experi-
enced pain, anxiety/depression, confusion, and other
symptoms, and more severe levels of each symptom in
the week of death. Symptom scores in the POS and EQ-
5 D will be compared for pain and anxiety/depression
and percentage and type of disagreements reported. We
will also compare item responses and total scores in the
POS, EQ-5 D and TRIG, satisfaction with the different
types of formal care (both as categorical - to identify
those experiencing poor care - and ordinal data - very
poor/poor/fair/good/very good/excellent) and attainment
of preferred place of death for patients and relatives,
between home and hospital, hospice and nursing home
deaths. Differences between home and hospital, hospice
or nursing home deaths will be tested using indepen-
dent-samples t-tests to compare normally distributed
continuous data, Mann-Whitney tests to compare non-
parametric continuous or ordinal data, and c2 tests to
compare categorical variables.
Frequency tables and descriptive statistics with num-
bers and percentages (95% CIs), medians (with IQ
ranges) or means (with SDs) will report the use of infor-
mal and formal care in the three months before death,
by place of death (objectives 1.4 and 1.5). Use will be
examined both as categorical (yes/no) and ordinal or
continuous data (median/mean depending on distribu-
tion normality of hours of care, numbers of visits and
admissions). Home deaths will be compared with the
three other places of deaths (one-to-one) using indepen-
dent-samples t-tests to compare normally distributed
continuous data, Mann-Whitney tests to compare non-
parametric continuous or ordinal data, and c2 tests to
compare categorical variables. Continuous data on ser-
vice use are expected to be skewed but we will examine
histograms and box plots to confirm this.
Data on service use in the last three months before
death, collected using the CSRI, will be combined with
appropriate unit costs to calculate service costs. Unit
costs will be mostly obtained from the 2009 Unit Costs
for Health and Social Care publication[43]. We plan to
cost the informal care by using the hourly wage rate of
a formal caregiver that would have to be paid to replace
informal care if this was not available (market price
method). Sensitivity analyses will be carried out by cal-
culating informal care costs using a lost productivity
method (time lost from work, i.e. human capital
approach). We will compute informal and formal care
costs, and total costs. The cost data are expected to be
skewed but we will examine histograms and box plots
to confirm this. Depending on normality, we will report
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mean or median costs per person per day and mean or
median total costs per person in the three months
before death. Differences between home and hospital,
hospice and nursing home deaths will be tested using
independent-samples t-tests or Mann-Whitney tests. We
will explore the relationship between costs and out-
comes in the different settings.
Similar analyses will be conducted to compare home
vs. institutional deaths (merging hospital, hospice, nur-
sing home deaths) (objective 2), to compare areas with
high vs. low home death rates and areas with high vs.
low deprivation levels (objective 3).
Multivariate analysis of factors influencing death at home
Following bivariate analyses comparing home with other
places of death, logistic regressions will be conducted to
determine the relative influence of different factors on
death at home (vs. hospital death and vs. institutional
death), place of death being the dependent categorical
variable (home - yes/no) (objective 4). Potential predic-
tors of death at home identified in bivariate analyses will
be entered in the regression. These will be grouped in
three categories - illness related, personal (including pre-
ferences), and environmental factors (including care
components), following a model of factors influencing
death at home in cancer [15]. Odds ratios with 95% CIs
will be calculated for each factor and compared to iden-
tify the strongest and most significant. Results will be
compared with the bivariate analysis to identify factors
that lose significance or strength to others. The adjusted
R2 statistic will be calculated to determine the amount
of variance accounted for in the models.
Regression analyses will be performed for areas with
high and low home death rates separately (sub-group
analysis) and results will be compared in terms of fac-
tors retained in the models and those that lose signifi-
cance or strength to others, and the amount of variance
explained. In the same way, regressions will also be per-
formed within areas with high and low social depriva-
tion levels.
Multivariate analysis of the influence of death at home on
outcomes and costs
Regression analyses will be conducted to determine the
relative influence of death at home (vs. hospital death
and vs. institutional death) on the costs (informal, for-
mal and total) and on each outcome (dependent vari-
ables), controlling for other factors (objective 5). First,
bivariate analyses will be undertaken to identify predic-
tors of each of the palliative outcomes and cost-drivers,
other than death at home; these will be entered in the
regression, alongside death at home. Different multivari-
ate approaches will be undertaken including logistic
regression and linear regression. We plan to use boot-
strapping with cost data as these are expected to be
skewed, to generate more robust 95% CIs;[44] results
will be compared to identify the best model.
The odds ratios and 95% CIs for death at home will
be compared with those for other factors, to assess its
strength and significance relative to others. Results will
be compared with bivariate analyses to examine whether
death at home lost or gain significance or strength.
Similar regression analyses will be performed for areas
with high and low home death rates separately (sub-
group analysis) and results will be compared in terms of
the influence of death at home. Regressions will also be
performed within areas with high and low social depri-
vation levels.
Power calculation
Sample size calculations were carried out following Alt-
man’s methods[45] for the main component of the ana-
lysis which will compare home deaths with institutional
deaths, to enable powered comparisons in terms of the
preferences for place of death and the use of and satis-
faction with home care. Calculations were based on esti-
mates from a London survey (1995-96) which also used
an adaptation of Cartwright’s questionnaire and com-
pared home deaths vs. those taking place elsewhere for
cancer patients [30]. Three variables were examined:
patient preference for death at home (yes/no), help of
community nurse (yes/no), and satisfaction with GP
care (poor vs. fair/good/excellent). Standardised differ-
ences in proportions were 0.11 in deceased who pre-
ferred to die at home, 0.72 in people who had help from
community nursing, and 0.22 in people dissatisfied with
GP care. Applying these to Altman’s nomogram (power
of 80%, significance of 0.05), it was estimated that a
sample of 30 would be sufficient to detect differences in
preferences of the same magnitude as in the previous
London survey, 60 would allow detection of differences
in the use of community nursing but a much bigger
sample size 800 would be needed to detect the same dif-
ferences in satisfaction with GP care (0.11 amongst
home deaths and 0.19 amongst deaths elsewhere were
dissatisfied with GP care, with a trend towards signifi-
cance in the previous study). On balance, we felt that
the difference in GP care was small and did not justify
the increase in sample size. Therefore, it was decided to
aim for a minimum standardised difference of 0.30
which will be detectable with a minimum sample of 350
bereaved relatives, split into home, hospital and hospice/
nursing home, home deaths and institutional deaths for
the main component of analysis and into home and hos-
pital deaths for the case-control analysis. A sample of
350 will also accommodate logistic and linear regression
analyses with a maximum of 35 variables entered and
19 retained, if the rules of thumb suggested by Altman
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apply (n/10 variables and square root of sample size
respectively) [45].
Lack of data on the magnitude of differences on
patients and relatives’ outcomes and costs precluded
further calculations. Measuring the costs of care usually
requires relatively large sample sizes due to high var-
iance in costs (large SDs)[46] but the cost component is
the more exploratory part of the analysis and will be
focused on estimation rather than hypothesis testing, as
so little is known about this. Post-hoc calculations will
be performed at the end of the study to determine the
power and significance of the findings.
Based on responses achieved in a recent survey, we
have accommodated a scenario of 38% response rate
with an extra 10% of missing data [26]. To get a sample
of ~350 completed questionnaires for the most detailed
level of analysis (case-control of home vs. hospital
deaths) we estimated we need to sample ~1,450 deaths
over a one year period. Data on numbers of cancer
deaths and of home deaths in each of the selected PCTs
provided by the Thames Cancer Registry [47], applied
against NHS acute hospital and hospice death rates and
nursing home death rates in the respective Cancer Net-
works(26;48) suggested our estimated sample was feasi-
ble, although temporal fluctuations were expected (the
study takes place in 2009/10).
Based on the estimated figures by place of death, a
sampling strategy was drawn. We decided to include all
eligible home deaths, hospice deaths and nursing home
deaths in all four PCTs, and a random sample of 150
NHS hospital deaths in each PCT. The number of peo-
ple to be sent questionnaires was projected to approxi-
mate 1,450, of which we expected ~550 returned
questionnaires, ~500 with complete data.
Interim analyses and stopping rules
Prior to commencing the study, it was decided that if
response rates were lower than 30% or if there were ser-
ious complaints that could not be addressed, we would
stop the study. Results from Wave 1 were reviewed with
the project steering group in March 2010. The response
rate achieved by then was higher than 40% and there
were no serious complaints that could not be addressed.
Therefore, the study progressed to Wave 2.
Project steering group
This consists of an independent group responsible for
data-monitoring. The group comprises representatives
of the ONS, the PCTs in the study, local palliative care
services, the Department of Heath End-of-Life Care
Team, and a user representative (bereaved relative).
Progress is reported to the group every three months.
Discussion
The QUALYCARE study faces two main challenges.
First, ethical and data protection issues and practicalities
are prominent in the study and have strongly deter-
mined its design. The sensitivity of the topic requires
complicated procedures, compassion and attention to
detail from all the staff involved. Secondly, there is a
lack of evidence in the emerging area of cost measure-
ment at the end of life to inform study design and pro-
cedures, thus methods and conclusions relating to costs
will be in essence exploratory. Recall bias and use of
caregivers as proxies for evaluating service use and pal-
liative outcomes are important aspects to consider when
interpreting the data [17,36].
Despite limitations, the QUALYCARE study is one of
the most detailed population-based surveys of our time
about the end-of-life care provided to people with can-
cer. Being carefully designed to be ethically and scientifi-
cally sound, it contributes to advancing the science in
end-of-life care research. Case-control studies such as
the one nested in QUALYCARE are rare in end-of-life
care research[49] despite offering a strong alternative to
longitudinal studies (which pose numerous practical,
ethical and methodological challenges in this field) for
studying natural variation in outcomes. Our health eco-
nomic evaluation component will add to pioneering
stages in the methodological development of cost mea-
surement at the end of life.
More importantly, the QUALYCARE study could dis-
cover variations in the underlying individual reality of
place of death for people dying from cancer and their
families. This may include differences in the preferences,
in palliative outcomes for patients, in bereavement out-
comes for relatives, and in the costs of caring for people
dying at home as compared to institutional settings, not
just for the health care system but for families. Our
findings will, we hope, help improve care for cancer
patients and their families locally, and in comparable
settings across the UK and beyond.
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